Scientific insights, company announcements, and industry perspectives from the Helix Therapeutics team.
Our Boston facility has completed the installation of a new automated large-scale peptide synthesiser, increasing our GMP production capacity by 300% to meet growing pharmaceutical demand for clinical-grade peptide APIs.
Read MoreThe explosive growth of GLP-1 peptide therapeutics is creating unprecedented demand for large-scale SPPS. Our experts share insights on overcoming key synthesis challenges including difficult sequences and scale-up purification.
Read MoreFollowing a comprehensive surveillance audit of our quality management systems by Bureau Veritas, Helix Therapeutics has received recertification under ISO 9001:2015, reaffirming our commitment to quality excellence.
Read MoreOur R&D team has validated a microwave-assisted SPPS protocol that dramatically reduces synthesis time for difficult sequences above 40 amino acids, without compromising coupling efficiency or crude purity.
Read MoreAs the cosmeceutical peptide market surpasses $2.1 billion, we examine the clinical evidence behind the most widely used bioactive peptide ingredients and what formulators should demand from their suppliers.
Read MoreA new distribution partnership with a leading Japanese life science reagent distributor brings Helix Therapeutics catalog peptides to researchers across Japan, South Korea, Taiwan, and Singapore.
Read MoreReceive quarterly updates on new products, scientific publications, and industry news directly in your inbox.
No spam. Unsubscribe at any time. See our Privacy Policy.